Page 8 - ஓநாய் வெபர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Immunomodulatory drugs improve the success rate of cancer therapies Immunomodulatory drugs, including the Contergan derivatives lenalidomide and pomalidomide, have significantly improved the therapy of hematologic malignancies such as multiple myeloma. Researchers at the Technical University of Munich (TUM) have now further decoded the mode of action in this class of medications. At the same time, they identified new innovative targeted cancer therapies. The drug thalidomide was sold as a sedative under the trade name Contergan in the 1950s and 1960s. At the time, its side-effects triggered one of the largest pharmaceutical scandals in history: The medication was taken from the market after it became known that the use of Contergan during pregnancy had resulted in over 10,000 cases of severe birth defects.

Arne skerraVanesa fernFlorian bassermannMichael heiderWolfgang weberEmily hendersonTechnical university of munichProfessor for nuclear medicineTechnical universityNuclear medicineBiological chemistryBirth defectsMultiple myelomaவனேசா ஃபெர்ன்மைக்கேல் ஹைடர்ஓநாய் வெபர்